IPO Update: Investors Chase Modest Immuno-Oncology Offerings

The two most recent US initial public offerings by drug developers were launched by companies in the immuno-oncology field – Hutchison China MediTech Ltd. (Chi-Med) and Corvus Pharmaceuticals Inc. – showing that investors still are intrigued by cancer immunotherapies, although not at a high IPO price.

More from Anticancer

More from Therapy Areas